Piperidou A, et al. - By analyzing evidence from randomized, controlled trials identified from major electronic databases, clinical trial registers, and sources of gray literature, researchers determined how albuminuria and proteinuria in patients with diabetes mellitus were potentially influenced by treatment with sodium-glucose cotransporter 2 (SGLT-2) inhibitors. In 15 studies with 17,540 patients, a statistically significant reduction in albuminuria was reported in relation to SGLT-2 inhibitors vs placebo or active control. A more prominent attenuation in urine albumin-to-creatinine ratio was reported in randomized, controlled trials that included subjects with moderately or severely increased albuminuria. Ultimately, systolic and diastolic blood pressure levels were attenuated by 4.43 mmHg and 1.81 mmHg, respectively, with the use of SGLT-2 inhibitors.